Human blood metabolites and risk of severe <scp>COVID</scp>‐19: A Mendelian randomization study
Weifeng Shang(Tongji Hospital), Dechang Chen(Shanghai Jiao Tong University), Zhenliang Wen(Shanghai Jiao Tong University), Xuan Shen(Shanghai Jiao Tong University), Hang Qian(Anhui Medical University), Sheng Zhang(Shanghai Jiao Tong University)
Cited by 5
Related Papers
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
|Nature Communications|2020|432
Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study
|Annals of Intensive Care|2020|146
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
|The Lancet Regional Health - Western Pacific|2023|112
Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
|bioRxiv (Cold Spring Harbor Laboratory)|2020|94
Expert consensus on the use of human serum albumin in critically ill patients
|Chinese Medical Journal|2021|70